Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden.

Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P.

Eur Urol. 2004 Dec;46(6):717-23; discussion 724.

PMID:
15548438
2.

Randomised prostate cancer screening trial: 20 year follow-up.

Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P.

BMJ. 2011 Mar 31;342:d1539. doi: 10.1136/bmj.d1539.

3.
4.
5.

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial.

Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, Chevrette E, Lévesque J.

Prostate. 2004 May 15;59(3):311-8.

PMID:
15042607
6.

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28.

PMID:
18262712
7.

Screening for prostate cancer: updated experience from the Tyrol study.

Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G.

Can J Urol. 2005 Feb;12 Suppl 1:7-13; discussion 92-3.

PMID:
15780158
8.

Percent free PSA as an additional measure in a prostate cancer screen.

Miele ME.

Clin Lab Sci. 2001 Spring;14(2):102-7.

PMID:
15625982
9.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

10.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team..

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.

PMID:
15770007
11.

Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden.

Holmberg H, Carlsson P, Löfman O, Varenhorst E.

Health Policy. 1998 Aug;45(2):133-47.

PMID:
10186224
12.
14.

Characteristics of prostate cancer detected by digital rectal examination only.

Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ.

Urology. 2007 Dec;70(6):1117-20.

PMID:
18158030
15.

The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.

Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström M, Hugosson J, Lundgren R, Stattin P, Törnblom M, Johansson JE.

Scand J Urol Nephrol. 2005;39(2):117-23.

PMID:
16019764
16.

[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].

Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. French.

PMID:
19559380
17.

Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study.

Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, Shapiro JA, Weiss NS.

Epidemiology. 2005 May;16(3):367-76. Erratum in: Epidemiology. 2005 Jul;16(4):515.

PMID:
15824554
18.

Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.

Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG.

Scand J Urol Nephrol. 2006;40(4):265-71.

PMID:
16916765
19.

Does educational printed material manage to change compliance with prostate cancer screening?

Stamatiou K, Skolarikos A, Heretis I, Papadimitriou V, Alevizos A, Ilias G, Karanasiou V, Mariolis A, Sofras F.

World J Urol. 2008 Aug;26(4):365-73. doi: 10.1007/s00345-008-0258-z. Epub 2008 Apr 18.

PMID:
18421460
20.

Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial.

Sennfält K, Sandblom G, Carlsson P, Varenhorst E.

Scand J Urol Nephrol. 2004;38(4):291-8.

PMID:
15669588

Supplemental Content

Support Center